Dopamine Function and Neuroleptics in Schizophrenia — Post-Mortem Studies of Human Brain Tissue
There is little doubt that biochemical investigation of human post mortem brain tissue has made a substantial contribution to the understanding and treatment of disease. It was as a direct result of the observation of a dopamine deficit in the corpus striatum of Parkinson’s disease patients that L-dopa was introduced and found to be so successful (Birkmayer and Hornykiewicz, 1962). More recently, substantial advances in our understanding of Huntington’s chorea and senile dementia have been gained from post mortem studies.
KeywordsDopamine Receptor Temporal Lobe Epilepsy Corpus Striatum Dopamine Concentration Neuroleptic Treatment
Unable to display preview. Download preview PDF.
- Borison, R.L., Fields, J.Z. and Diamond, R.I., 1981, Site specific blockade of dopamine receptors by neuroleptic agents in human brain. Neuropharmacol., 20:1321.Google Scholar
- Crow, T.J., Owen, F., Cross, A.J., Ferrier, N., Johnstone, E.C., McCreadie, R.M., Owens, D.G.C. and Poulter, M., 1981, Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia: evidence that an increase in D2 dopamine receptors is associated with the type 1 syndrome, in: Transmitter biochemistry of human brain tissue, P. Riederer and E. Usdin eds., Macmillan, London, P.85.Google Scholar
- Reynolds, G.P., 1983, Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia, Nature (in press).Google Scholar
- Reynolds, G.P., Riederer, P., Jellinger, K. and Gabriel, E., 1981, Dopamine receptors and schizophrenia: the neuroleptic drug problem, Neuropharmacol., 20:1319.Google Scholar